Nothing Special   »   [go: up one dir, main page]

ATE380875T1 - Chimäre proteine zur vermeidung der komplementaktivierung - Google Patents

Chimäre proteine zur vermeidung der komplementaktivierung

Info

Publication number
ATE380875T1
ATE380875T1 AT94931763T AT94931763T ATE380875T1 AT E380875 T1 ATE380875 T1 AT E380875T1 AT 94931763 T AT94931763 T AT 94931763T AT 94931763 T AT94931763 T AT 94931763T AT E380875 T1 ATE380875 T1 AT E380875T1
Authority
AT
Austria
Prior art keywords
chimeric proteins
complement activation
avoid complement
avoid
polypeptide
Prior art date
Application number
AT94931763T
Other languages
English (en)
Inventor
Jone-Long Ko
Paul J Higgins
C Grace Yeh
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Application granted granted Critical
Publication of ATE380875T1 publication Critical patent/ATE380875T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT94931763T 1993-09-24 1994-09-23 Chimäre proteine zur vermeidung der komplementaktivierung ATE380875T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12659693A 1993-09-24 1993-09-24
US08/310,416 US5679546A (en) 1993-09-24 1994-09-22 Chimeric proteins which block complement activation

Publications (1)

Publication Number Publication Date
ATE380875T1 true ATE380875T1 (de) 2007-12-15

Family

ID=26824842

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94931763T ATE380875T1 (de) 1993-09-24 1994-09-23 Chimäre proteine zur vermeidung der komplementaktivierung

Country Status (9)

Country Link
US (2) US5679546A (de)
EP (1) EP0723555B1 (de)
JP (2) JP3860605B2 (de)
CN (1) CN1057097C (de)
AT (1) ATE380875T1 (de)
AU (1) AU697167B2 (de)
CA (1) CA2172610A1 (de)
DE (1) DE69435049D1 (de)
WO (1) WO1995008570A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6482404B1 (en) 1989-10-12 2002-11-19 David James White Transplantation of tissue comprising a DNA sequence encoding a homologous complement restriction factor
US5866402A (en) * 1995-05-05 1999-02-02 Chiron Corporation Chimeric MCP and DAF proteins with cell surface localizing domain
FR2736916B1 (fr) * 1995-07-21 1997-09-19 Univ Paris Curie Proteines hetero-multimeriques recombinantes du type alpha-beta c4bp
EP0996461B1 (de) * 1997-10-31 2005-01-12 Walter Reed Army Institute of Research Verwendung von inhibitoren der komplementaktivierung zur herstellung eines medikaments zur inhibierung von nebenwirkungen von pharmazeutischen zusammensetzungen, die amphiphile träger oder wirkstoffträger moleküle enthalten
NZ506920A (en) * 1998-02-20 2003-12-19 Tanox Inc Inhibitors of complement activation
US7112327B2 (en) 1998-02-20 2006-09-26 Tanox, Inc. Inhibition of complement activation
US6956107B2 (en) * 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
US6297024B1 (en) 1998-10-15 2001-10-02 Cell Activation, Inc. Methods for assessing complement activation
US6235494B1 (en) 1999-02-08 2001-05-22 The Scripps Research Institute Substrates for assessing mannan-binding protein-associated serine protease activity and methods using the substrates
AU2400500A (en) * 1999-11-01 2001-05-14 Chiron Corporation Expression vectors, transfection systems, and method of use thereof
DK1325033T3 (da) 2000-10-10 2010-04-06 Genentech Inc Inhibering af komplement C5 aktivering til behandlingen og forebyggelsen af forsinket xenograf- eller akut vaskulær afstødning
US6820011B2 (en) * 2001-04-11 2004-11-16 The Regents Of The University Of Colorado Three-dimensional structure of complement receptor type 2 and uses thereof
NZ529044A (en) * 2001-06-08 2008-03-28 Novartis Ag Treatment or prophylaxis of insulin-producing cell graft rejection
WO2004024889A2 (en) * 2002-09-16 2004-03-25 Elusys Therapeutics, Inc. Production of bispecific molecules using polyethylene glycol linkers
AU2003298650B2 (en) * 2002-11-15 2010-03-11 Musc Foundation For Research Development Complement receptor 2 targeted complement modulators
WO2005069726A2 (en) * 2004-01-21 2005-08-04 Case Western Reserve University Hybrid and chimeric polypeptides that regulate activation of complement
JP5137053B2 (ja) * 2004-02-10 2013-02-06 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト 抗ｂ因子抗体もしくはその抗原結合性フラグメント、それを含む組成物、抗原結合性ポリペプチド、および治療薬
US8703693B2 (en) * 2004-03-31 2014-04-22 The Feinstein Institute For Medical Research Adrenomedullin and adrenomedullin binding protein for ischemia/reperfusion treatment
DE602005026794D1 (de) * 2004-03-31 2011-04-21 The Feinstein Inst Medical Res Adrenomedullin und adrenomedullin-bindungsprotein zur ischämie/reperfusionsbehandlung
CN103505728A (zh) * 2005-05-26 2014-01-15 科罗拉多大学评议会法人机构 用于治疗外伤性脑损伤、脊髓损伤及相关病症的补体旁路抑制
HUE026423T2 (en) * 2005-11-04 2016-05-30 Genentech Inc Use of complement biosynthetic pathway inhibitors for treating eye diseases
PL2044111T3 (pl) * 2006-06-21 2015-02-27 Musc Found For Res Dev Celowanie czynnika H dopełniacza do leczenia chorób
DK2907827T3 (da) 2006-11-02 2019-01-02 Genentech Inc Humaniserede anti-faktor D-antistoffer og anvendelser deraf
NZ578873A (en) * 2007-03-01 2012-01-12 Wellstat Ophthalmics Corp Complement factor B analogs and uses for the treatment of complement mediated disease such as inflammation
US7964705B2 (en) 2007-03-14 2011-06-21 Taligen Therapeutics, Inc. Humaneered anti-factor B antibody
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
US20090324585A1 (en) * 2008-06-12 2009-12-31 The Trustees of the Leland Standford Junior University Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis
US9066925B2 (en) 2009-07-02 2015-06-30 Musc Foundation For Research Development Methods of stimulating liver regeneration
WO2011057158A1 (en) 2009-11-05 2011-05-12 Taligen Therapeutics, Inc. Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
CN102234332B (zh) * 2010-04-26 2014-12-17 浙江海正药业股份有限公司 一种重组人血白蛋白及其融合蛋白的分离纯化工艺
EP2569332B1 (de) 2010-05-14 2019-01-09 The Regents of the University of Colorado, A Body Corporate Verbesserte komplement-rezeptor-2-anzielungsgruppen
JP2013533243A (ja) 2010-06-22 2013-08-22 ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレート 補体成分３のＣ３ｄ断片に対する抗体
CN106620693A (zh) 2010-09-03 2017-05-10 艾伯维施特姆森特克斯有限责任公司 新型调节剂及使用方法
CN103796667A (zh) 2011-06-22 2014-05-14 艾普莱斯制药公司 用补体抑制剂治疗慢性障碍的方法
AU2013243570B2 (en) * 2012-04-03 2017-12-14 Novelmed Therapeutics, Inc. Humanized and chimeric anti-factor Bb antibodies and uses thereof
EP2855529A4 (de) 2012-05-24 2015-12-09 Alexion Pharma Inc Humanisierte anti-faktor-b-antikörper
WO2014028865A1 (en) 2012-08-17 2014-02-20 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
SG11201601044XA (en) 2013-08-12 2016-03-30 Genentech Inc Compositions and method for treating complement-associated conditions
WO2015130826A1 (en) 2014-02-27 2015-09-03 Allergan, Inc. COMPLEMENT FACTOR Bb ANTIBODIES
PE20161440A1 (es) 2014-05-01 2017-01-26 Genentech Inc Variantes del anticuerpo anti-factor d y sus usos
RU2698205C2 (ru) 2014-12-18 2019-08-23 Ф. Хоффманн-Ля Рош Аг Способ определения антител, вызывающих комплемент-зависимую цитотоксичность
IL258024B2 (en) * 2015-09-24 2023-03-01 Univ Pennsylvania A preparation and method for the treatment of a complement-mediated disease
EP3368074A2 (de) 2015-10-30 2018-09-05 Hoffmann-La Roche AG Anti-faktor-d-antikörper und -konjugate
CN108472382A (zh) 2015-10-30 2018-08-31 豪夫迈·罗氏有限公司 抗-因子d抗体变体缀合物及其用途
JP6771568B2 (ja) * 2015-12-23 2020-10-21 グリーンオヴェイション・バイオテック・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＧｒｅｅｎｏｖａｔｉｏｎ Ｂｉｏｔｅｃｈ Ｇｍｂｈ 補体活性化を抑制するポリペプチド
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
EP3956347A4 (de) * 2019-04-13 2023-09-20 National Centre For Cell Science Chimäre daf-mcp-proteine, verfahren zu deren herstellung und verwendung des chimären proteins zur behandlung pathologischer zustände in zusammenhang mit dem komplementsystem

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5212071A (en) * 1988-04-01 1993-05-18 The Johns Hopkins University Nucleic acids encoding a human C3b/C4b receptor (CR1)
US4774180A (en) * 1986-02-26 1988-09-27 Massachusetts Institute Of Technology Construction and application of polyproteins
US5264357A (en) * 1985-05-24 1993-11-23 Genentech, Inc. Nucleic acids vectors and cells for the synthesis of membrane anchor fusion polypeptides
IL82390A0 (en) * 1986-05-02 1987-10-30 Genentech Inc Nucleic acid and methods for the synthesis of novel daf compositions
ATE103932T1 (de) * 1989-08-22 1994-04-15 Immunex Corp Fusionsprotein bestehend aus gm-csf und il-3.
CA2049964A1 (en) * 1990-01-26 1991-07-27 Mark P. Pasek C4 binding protein fusion proteins
EP0512733A2 (de) * 1991-05-03 1992-11-11 Washington University Modifizierter Komplementsystemregler
US5252216A (en) * 1992-03-24 1993-10-12 Smithkline Beecham Corporation Protein purification
US5627264A (en) * 1994-03-03 1997-05-06 Alexion Pharmaceuticals, Inc. Chimeric complement inhibitor proteins

Also Published As

Publication number Publication date
JPH09502985A (ja) 1997-03-25
CN1057097C (zh) 2000-10-04
EP0723555A1 (de) 1996-07-31
AU697167B2 (en) 1998-10-01
WO1995008570A1 (en) 1995-03-30
DE69435049D1 (de) 2008-01-24
CA2172610A1 (en) 1995-03-30
JP2005041882A (ja) 2005-02-17
EP0723555B1 (de) 2007-12-12
US5851528A (en) 1998-12-22
CN1138863A (zh) 1996-12-25
US5679546A (en) 1997-10-21
AU8071994A (en) 1995-04-10
JP3860605B2 (ja) 2006-12-20
EP0723555A4 (de) 1999-04-28

Similar Documents

Publication Publication Date Title
ATE380875T1 (de) Chimäre proteine zur vermeidung der komplementaktivierung
NO971875D0 (no) Cathepsin 02 protease
TW430669B (en) A hybrid toxin fragment and their use
ATE189475T1 (de) Wachstums-differenzierungsfaktor der tgf-b familie
ATE226634T1 (de) Fibronektin bindendes protein
ATE328101T1 (de) Strukturprotein von adeno-assoziiertem virus mit veränderten chromatographischen eigenschaften
ATE476495T1 (de) Bazillus thuringiensis und dessen insektizide proteine
HK51197A (en) Platelet blocking peptides
ES2058479T3 (es) Compuestos peptidicos.
ATE285474T1 (de) Haemophilus adhäsionsproteinen
PT635025E (pt) Processo para preparar proteinas modificadas
ES2052513T3 (es) Nuevos polipeptidos, su fabricacion y empleo.
FI946076A (fi) Modifioituja Kluyveromyces-hiivoja, valmistus ja käyttö
AU669149B2 (en) Expression signal-peptide-free staphylokinases
ATE256747T1 (de) Glykosyltransferase expression in aspergillus
DE3881123D1 (de) Klonieren von fuer einen antibakteriellen polypeptidvorlaeufer kodierender dna und expression des vorlaeufers.
EP0714982A3 (de) Chimäre Proteine mit fibrinolytischen und thrombinhemmenden Eigenschaften
DE69033553D1 (de) Rekombinante herstellung von laktoperoxidase
DE68917536D1 (de) Methode zur Reduktion von aromatischen Amino-Gruppen.
DK0858465T3 (da) Protein med antitumorvirkning.
MX9701904A (es) Proteinas de enlace de pka novedosas y usos de las mismas.
ATE76081T1 (de) Verfahren zur herstellung von dipeptiden mit nterminalen nichtproteinogenen aminosaeuren.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties